ESMO 2026: KEYNOTE-B49 – Pembrolizumab in Advanced Breast Cancer
At the ESMO Congress 2026, Dr. Hope Rugo, MD, FASCO, Director of the Women's Cancers Program and Division Chief of Breast Medical Oncology at City of Hope Comprehensive Cancer Center, California, USA, presented a late-breaking abstract on the results of the phase III KEYNOTE-B49 trial. Pembrolizumab plus chemotherapy improved progression-free survival in patients with HR-positive, HER2-negative advanced breast cancer, particularly those with higher PD-L1 expression. Dr. Rugo also highlights the need for better biomarkers to identify patients who may benefit from immunotherapy.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in







